These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15600200)

  • 21. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
    Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
    Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen.
    Rendell MS; Glazer NB; Ye Z
    J Diabetes Complications; 2003; 17(4):211-7. PubMed ID: 12810245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors.
    Fonseca VA; Theuma P; Mudaliar S; Leissinger CA; Clejan S; Henry RR
    J Diabetes Complications; 2006; 20(1):14-20. PubMed ID: 16389162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
    Roden M; Mariz S; Brazzale AR; Pacini G
    J Intern Med; 2009 Apr; 265(4):476-87. PubMed ID: 19298459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics.
    Hu YY; Ye SD; Zhao LL; Zheng M; Chen Y
    Eur J Clin Invest; 2010 Jul; 40(7):571-4. PubMed ID: 20482594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.
    Van Raalte DH; van Genugten RE; Eliasson B; Möller-Goede DL; Mari A; Tura A; Wilson C; Fleck P; Taskinen MR; Smith U; Diamant M
    Eur J Endocrinol; 2014 Apr; 170(4):565-74. PubMed ID: 24421302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
    Kim HJ; Jeong IK; Hur KY; Kim SK; Noh JH; Chun SW; Kang ES; Rhee EJ; Choi SH
    Diabetes Metab J; 2022 Sep; 46(5):689-700. PubMed ID: 35295073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
    Charbonnel B; Roden M; Urquhart R; Mariz S; Johns D; Mihm M; Widel M; Tan M
    Diabetologia; 2005 Mar; 48(3):553-60. PubMed ID: 15739120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
    Bell DS; Dharmalingam M; Kumar S; Sawakhande RB
    Diabetes Obes Metab; 2011 Sep; 13(9):800-5. PubMed ID: 21477065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.
    Hiroi S; Sugiura K; Matsuno K; Hirayama M; Kuriyama K; Kaku K; Kawakami K
    Diabetes Technol Ther; 2013 Feb; 15(2):158-65. PubMed ID: 23289434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical effect of combination therapy of pioglitazone and an alpha-glucosidase inhibitor.
    Seino H; Yamaguchi H; Misaki A; Sakata Y; Kitagawa M; Yamazaki T; Kikuchi H; Abe R
    Curr Med Res Opin; 2003; 19(8):675-82. PubMed ID: 14687436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
    Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes.
    Khan M; Murray FT; Karunaratne M; Perez A
    Diabetes Obes Metab; 2006 Jan; 8(1):31-8. PubMed ID: 16367880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
    Aljabri K; Kozak SE; Thompson DM
    Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Gomis R; Espadero RM; Jones R; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2011 Jul; 13(7):653-61. PubMed ID: 21410628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.